MitoFit Preprints 2022.14
doi:10.26124/mitofit:2022-0014
Open Access

Review

Cite
Åsander Frostner E, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. MitoFit Preprints 2022.14. https://doi.org/10.26124/mitofit: 2022-0014

Author contributions
Data collection and evaluation was performed by EAF, SSS and IC. All authors wrote the manuscript. EAF, SSS and IC designed the framework of the review.

Conflicts of interest
The authors are employees of Abliva AB, which holds the commercial rights to KL1333, NV189 and NV354. All authors own shares in Abliva.

Received 2022-04-14
Accepted 2022-04-15
Online 2022-04-20

Keywords
mitochondrial disease, clinical development, mechanism of action, small molecules, industrial sponsors

Towards a treatment for mitochondrial disease: current compounds in clinical development

Eleonor Åsander Frostner[1,2†], Sonia Simón Serrano[1,2†], Imen Chamkha[1,2], Ellen Donnelly[1], Eskil Elmér[1,2], Magnus J Hansson[1,2*]

[1] Abliva AB, Medicon Village, 223 81 Lund, Sweden.
[2] Mitochondrial Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

† Equal contribution
* Corresponding author: magnus.hansson@abliva.com

Abstract

Primary mitochondrial diseases are a heterogeneous group of rare genetic disorders affecting approximately 125 persons per million. Mutations underlying these diseases give rise to biological changes (including decrease in energy production and increase in reactive oxygen species), leading to organ failure, and commonly early morbidity. Mitochondrial diseases often present in early childhood and lead to the development of severe symptoms, with severe fatigue and myopathy being some of the most prevalent and debilitating ones.
There is currently no cure for primary mitochondrial diseases, nor any approved pharmaceutical treatments for multisystemic disorders.
Present drug development in mitochondrial diseases focuses mainly on modulation of oxidative stress, regulation of the expression of genes involved in metabolic pathways, modulation of coenzymes, induction of mitochondrial biogenesis, and energy replacement.
In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsor.

1. Introduction

1.1. Primary mitochondrial diseases

Primary mitochondrial diseases are a heterogeneous group of rare genetic disorders which all stem from a defect in the cell's energy-producing organelles–the mitochondria. These diseases, often devastating, are caused by mutations in the nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) which encode mitochondrial components such as subunits of the electron transfer system (ETS), mitochondrial assembly proteins, or factors regulating mtDNA translation [1] and give rise to biological changes (including decrease in energy production, deregulation of calcium signaling, and increase in reactive oxygen species) [2]. In affected individuals, these harmful cellular processes lead to cell death, tissue and organ failure, and in many cases early morbidity.

Affecting approximately 125 persons per 1,000,000 [3], mitochondrial diseases often present in early childhood and lead to severe symptoms such as fatigue, myopathy (muscle weakness and/or exercise intolerance), heart failure, mental retardation, movement disorders, and epileptic seizures [4]. Among these, fatigue (typically together with myopathy) is one of the most prevalent and debilitating effects irrespective of sex, age or genotype [5]. In affected children, where Leigh syndrome is the most common mitochondrial disorder, regressive neurological symptoms are dominant [6]. In adults, a spectrum of diseases caused by the mtDNA point mutation m.3243A>G, with clinical presentations such as mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes and deafness (MIDD), is one of the most common groups of primary mitochondrial diseases [3].

1.2. Diagnostics and current standard of care for patients with mitochondrial diseases

Symptoms of mitochondrial disease can arise in any organ, at any age, and with varying severity. In fact, in many cases the clinical phenotype is unspecific [7], making these diseases difficult to diagnose. Together with the patient's family history, diagnostics have mainly relied on criteria scoring systems specifically for mitochondrial diseases which take into account the clinical, biochemical and imaging findings and their importance [8], often involving the need of a muscle biopsy.

In recent years, great advances within diagnostics of mitochondrial diseases have been made with the increasing availability of Whole Genome/Exome Sequencing (WGS/WES) [9]. Moreover, serum biomarkers of mitochondrial dysfunction is an emerging field, and fibroblast growth factor 21 (FGF21) and growth/differentiation factor 15 (GDF15) levels have recently been described to correlate with disease severity in muscle [10]. In addition, a recent study confirmed the depletion of the co-enzyme and co-substrate nicotinamide adenine dinucleotide (NAD^+), a central molecule in metabolism, including the ETS, in mitochondrial disease patients suffering from myopathy [11].

There is currently no cure for primary mitochondrial diseases, nor any approved pharmaceutical treatments for multisystemic disorders. To date, the treatment strategies are mainly symptomatic, and limited to dietary supplementation with amino acids, antioxidants and other supplements (e.g. carnitine, creatine, riboflavin, coenzyme Q10 (CoQ_{10}), and vitamin K with ascorbate) [12, 13], based on circumstantial evidence (no

evidence of efficacy from properly controlled clinical studies). In some cases, therapy is palliative only [1].

To date, the synthetic antioxidant Raxone® (idebenone, a CoQ_{10} analog) is the only drug that has been approved, by the European Medicines Agency (EMA), for a mitochondrial disease, specifically for Leber's Hereditary Optic Neuropathy (LHON), a disorder affecting the optic nerve, leading to progressive loss of central vision on both eyes. However, no evidence for the efficacy of either idebenone or other specific pharmaceutical compounds, in multisystemic mitochondrial diseases, have yet been demonstrated.

1.3. Aim and methods

Current drug development in mitochondrial diseases focuses on certain mechanisms of action, including modulation of oxidative stress, regulation of the expression of genes involved in metabolic pathways, modulation of coenzymes, induction of mitochondrial biogenesis, energy replacement, and specific cell- or gene therapy. In this short review, we present the current landscape of systemic mitochondrial disease drug development, focusing on small molecules in ongoing clinical trials conducted by industrial sponsors. In addition to literature search, sources have been the www.clinicaltrials.gov website and the targeted drug development companies' websites.

2. Compounds for the treatment of primary mitochondrial diseases in ongoing clinical trials

A large percentage of the planned or ongoing clinical studies of mitochondrial disease are being conducted by pharmaceutical companies testing small molecules in healthy volunteers and/or patients with systemic mitochondrial diseases (Supplementary Table 1).

2.1. Metabolic reprogramming and mitochondrial biogenesis

NADH:quinone oxidoredutase (NQO1) is an antioxidant cytoplasmic flavoprotein that reduces quinones into hydroquinones by transferring two electrons from NADH to NAD^+, increasing the intracellular NAD^+ concentration [14-16]. SIRT1, a NAD^+-dependent protein deacetylase from the family of silent information regulator [17], has been shown to regulate several metabolic pathways such as mitochondrial biogenesis, gluconeogenesis, lipolysis and fatty acid oxidation [17, 18]. Mitochondrial biogenesis can increase the cell efficiency by requiring less oxygen to produce an equal amount of energy and by reducing ROS production [19]. **KL1333** is an orally bioavailable synthetic ortho-quinone in clinical development by Abliva AB in collaboration with Yungjin Pharmaceuticals. *In vitro* studies in MELAS patient cells showed that KL1333 was able to restore NAD^+/NADH levels through NQO1 activity and activate the SIRT1/AMPK/PGC-1α pathway, increasing mitochondrial biogenesis. In addition, the reduced form of KL1333 was able to transport electrons to cytochrome *c* in a cell-free assay [20]. KL1333 has been clinically evaluated in a combined Phase Ia/b study in healthy volunteers and patients with primary mitochondrial diseases confirming its safety and tolerability as well as showing promising trends of improvement of fatigue and functional muscle strength in patients treated with active drug compared to placebo [21]. A registrational Phase II/III study is planned to start in 2022.

Peroxisome proliferator-activated receptor delta (PPARδ), a nuclear receptor and transcription factor, is part of the steroid hormone receptor superfamily [22]. Endogenous ligands of PPARδ are mainly lipids [23], inducing an increase in the mitochondrial capacity to oxidize fatty acids [24]. PPARδ has been proposed as a therapeutic target in metabolic syndrome through its regulation of metabolism in skeletal muscle, the heart, the liver, and adipose tissue [25].

Synthetic agonists of PPARδ have been shown to modulate PPARδ activity *in vivo* [25, 26]. The small molecule **bocidelpar sulphate** (**ASP0367**), developed by Mitobridge, a subsidiary to Japanese Astellas Pharma, is described as a PPARδ modulator, and has been tested in a Phase I clinical trial in healthy volunteers. Results showed no harmful effects, and the upregulation of PPARδ target genes was observed [27].The company is currently recruiting primary mitochondrial disease patients with myopathy in a Phase II/III study, assessing the effect of bocidelpar sulphate on functional improvement and fatigue.

US-based Reneo Pharmaceuticals is similarly developing a PPARδ agonist, **REN001**. Results from a concluded proof-of-concept Phase I study in patients with mitochondrial fatigue showed, according to the company, promising improvements in a walk test and in symptoms questionnaires. Reneo is currently recruiting patients in a Phase II/III study in mitochondrial myopathy patients, primarily investigating the effect of REN001 on improvements in the distance walked in a walk test.

US Cyclerion Therapeutics' **CY6463**, described as a CNS-penetrant soluble guanylate cyclase stimulator, is in development for the treatment of a subset of neurological conditions, including MELAS. Guanylate cyclase is an important enzyme of the nitric oxide signaling pathway and catalyzes synthesis of the second messenger cGMP [28]. cGMP, in turn, drives the activation of protein kinases, ion channels, and phosphodiesterases [29], and has been shown to induce mitochondrial biogenesis as well as ATP formation [30]. In preclinical studies, CY6463 has been shown to improve neuronal activity, mediate neuroprotection, and increase cognitive performance [31]. The company is currently investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the compound in a Phase IIa study in MELAS patients with neurological manifestations. In addition, Cyclerion will assess near-term impact on disease-specific biomarkers, brain perfusion, neurodegeneration, and cognition.

2.2. Energy replacement and substrate enhancement

Complex I (CI) dysfunction, one of the most common mitochondrial impairments, can cause a NAD^+/NADH imbalance and a decrease in mitochondrial membrane potential [32, 33]. Patients presenting with primary mitochondrial disorders with CI, or upstream, dysfunction could benefit from additional energetic inputs to Complex II (CII)/succinate dehydrogenase. Due to the lack of passive transport of succinate in the cellular membrane, extracellular succinate treatment would result in limited effects. Abliva AB, in collaboration with Isomerase Therapeutics, have designed and tested permeable succinate prodrugs. NV189, the first generation of permeable succinate prodrugs, was able to ameliorate the increase of lactate production in chemically CI-inhibited human platelets and increase the spare respiratory capacity of Leigh syndrome patient-derived fibroblasts [34]. **NV354,** the second generation of cell membrane permeable succinate, has been designed as an oral chronic treatment of Leigh syndrome. Due to its high brain

exposure, NV354 might potentially be tested for other mitochondrial diseases with neurological symptoms such as MELAS or LHON. A clinical Phase I trial is planned to start in 2022.

Similar to Leigh syndrome patients, children suffering from the ultra-rare mtDNA depletion syndrome thymidine kinase 2 (TK2) deficiency have a short life expectancy. TK2 serves a role in the supply of deoxynucleotides for mtDNA synthesis, and patients with TK2 deficiency exhibit severe myopathy and ultimately respiratory failure. The drug candidate **MT1621**, containing pyrimidine nucleosides, has been developed by US Modis Therapeutics (subsidiary of Zogenix, which was recently acquired by Belgian UCP), for the treatment of TK2 deficiency. Results from a retrospective Phase II observational study with MT1621 in TK2 deficiency patients showed an improved survival and scores in predefined response thresholds, and some patients regained functions that they had previously lost. MT1621 is about to be evaluated in a Phase III single-arm study in children and adolescents, primarily evaluating the proportion of subjects acquiring a motor milestone.

2.3. Regulation of reactive oxygen species

Mitochondria are the main producers of reactive oxygen species (ROS) such as superoxide anion (O_2-), produced mainly in CI and CIII and converted to H_2O_2 by superoxide dismutase (SOD) [35]. Pathological ROS levels due to dysfunction in the oxidative phosphorylation (OXPHOS) can lead to oxidative stress, imbalanced ROS production and antioxidant cellular capacity, leading to cellular damage of macromolecules [36].

Sonlicramol (KH176) is an orally bioavailable hydrophilic vitamin E-based compound from Dutch Khondrion BV. Sonlicromanol has a multi-modal mechanism acting both as ROS-redox modulator, and having anti-inflammatory properties due to the inhibition of mPGES-1 [37]. Safety and tolerability of sonlicromanol were confirmed in patients with mitochondrial disease with m.3243A>G mutation [38]. Its efficacy for cognitive functioning is currently being evaluated in a Phase IIb trial and will be further evaluated for long-term effects for patients that have completed the previous study. In addition, sonlicromanol will also be tested in children (<17 years old) with confirmed mitochondrial disorders with oxidative phosphorylation defects suffering from motor symptoms (Phase II).

Elamipretide (SS-31, MTP-131, Bendavia) developed by US Stealth Biotherapeutics, is a permeable tetrapeptide that reaches and localizes in the inner mitochondrial membrane. Elamipretide targets cardiolipin, a phospholipid situated in the inner mitochondrial membrane important for mitochondrial morphology [39], improving the cristae architecture, decreasing pathogenic ROS production and increasing ATP generation [40, 41]. The tolerability and efficacy of elamipretide has been clinically tested for genetically confirmed primary mitochondrial myopathy (PMM) patients. The results indicated that elamipretide was well-tolerated, and an increased trend of improvement in the six-minute Walk Test (6MWT) (primary endpoint) was observed without statistical significance in a phase II trial [40]. During Phase III, the evaluation of efficacy did not meet the primary endpoints which included 6MWT and total fatigue score on the Primary Mitochondrial Myopathy Symptom Assessment (PMMS assessment). Posthoc analysis revealed a significant difference in the primary endpoint on nDNA-related PMM.

Therefore, a Phase III clinical trial will be performed to evaluate the efficacy of elamipretide in PMM patients with repliosome-related nDNA mutations.

Barth syndrome is a primary mitochondrial disorder giving rise to symptoms such as skeletal muscle weakness and cardiomyopathy. Interestingly, Barth syndrome patients can present cardiolipin abnormalities leading to altered mitochondrial morphology, increased ROS levels and alterations in the ETS [42]. Clinical Phase II and III trials have been performed for the evaluation of safety, tolerability, and efficacy (6MWT, Barth Syndrome-Symptom Assessment) in genetically confirmed Barth syndrome patients. In part 1 of the study, no significant improvements were observed after 12 weeks of elamipretide exposure in a placebo-controlled crossover trial. The evaluation of long term exposure in an open label extension (part 2) resulted in an overall good tolerability of elamipretide with potential improvements over time [43].

Vatiquinone, (EPI-743, ATQ3) is a para-benzoquinone from PTC Therapeutics (former BioElectron and Edison Pharmaceuticals) derived from the hydrolysis of vitamin E [44]. When compared to Q10 and idebenone, vatiquinone presented up to ten-thousand times higher protective activity against oxidative stress [44, 45] and had the capacity to replenish the reduced form of the glutathione pool [44-46]. Moreover, vatiquinone inhibited 15-lipoxygenase (15-LO) which decreased lipid oxidation and protected Leigh syndrome patient-derived fibroblasts against ferroptosis, a type of cell death that can be activated due to an imbalance in glutathione peroxidase 4 and 15-LO activity [47]. Vatiquinone safety, oral bioavailability and capacity to penetrate the blood-brain barrier have also been confirmed [44, 45]. Vatiquinone has been approved for the treatment of patients with genetically confirmed respiratory chain disorder that are within 90 days of end of life care [45]. Vatiquinone is currently being evaluated in a phase II/III with mitochondrial disease patients presenting refractory epilepsy to evaluate efficacy in observable motor seizures for 28 days as primary outcome.

3. Conclusions

Historically, drug development within primary mitochondrial diseases, and other rare diseases, has fallen behind, due in large part to the complexity of identifying, recruiting and treating these rare patients. The growing understanding of mitochondrial disease complexity, heterogeneity, and the underlying genetics, as well as the shift towards patient involvement in drug development, have gradually changed this. Moreover, going back to 1983, the US Congress enacted a new law, the Orphan Drug Act, to reduce the cost and provide financial incentive for developing drugs for rare conditions, so called orphan drugs, by offering tax credits, a waiver of the Prescription Drug User Fee, and extended market exclusivity options [48]. Today, due to its success, orphan drug legislation also exists in the EU, Singapore, Japan, Australia, South Korea, and Taiwan [49].

Currently, there are more than 100 ongoing or planned clinical interventional studies listed in www.clinicaltrials.gov investigating the safety and/or efficacy of potential treatments for patients with primary mitochondrial diseases. These clinical trials are focused on dietary supplements, medical devices, gene therapy, mitochondrial supplementation, mitochondrial donation *in vitro* fertilization, new treatment approaches, and small molecules. The interest in mitochondrial medicine is clearly increasing, and we anticipate and hope that new treatments will become available to primary mitochondrial disease patients within the next few years.

References

[1] M. Moggio *et al.*, "Mitochondrial disease heterogeneity: a prognostic challenge," *Acta Myol,* vol. 33, no. 2, pp. 86-93, Oct 2014. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/25709378.

[2] M. R. Duchen, "Roles of mitochondria in health and disease," *Diabetes,* vol. 53 Suppl 1, pp. S96-102, Feb 2004, doi: 10.2337/diabetes.53.2007.s96.

[3] G. S. Gorman *et al.*, "Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease," *Ann Neurol,* vol. 77, no. 5, pp. 753-9, May 2015, doi: 10.1002/ana.24362.

[4] O. M. Russell, G. S. Gorman, R. N. Lightowlers, and D. M. Turnbull, "Mitochondrial Diseases: Hope for the Future," *Cell,* vol. 181, no. 1, pp. 168-188, Apr 2 2020, doi: 10.1016/j.cell.2020.02.051.

[5] G. S. Gorman *et al.*, "Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease," *Neuromuscul Disord,* vol. 25, no. 7, pp. 563-6, Jul 2015, doi: 10.1016/j.nmd.2015.03.001.

[6] R. J. Tinker, A. Z. Lim, R. J. Stefanetti, and R. McFarland, "Current and Emerging Clinical Treatment in Mitochondrial Disease," *Mol Diagn Ther,* vol. 25, no. 2, pp. 181-206, Mar 2021, doi: 10.1007/s40291-020-00510-6.

[7] P. Witters *et al.*, "Revisiting mitochondrial diagnostic criteria in the new era of genomics," *Genet Med,* vol. 20, no. 4, pp. 444-451, Apr 2018, doi: 10.1038/gim.2017.125.

[8] D. M. Niyazov, S. G. Kahler, and R. E. Frye, "Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment," *Mol Syndromol,* vol. 7, no. 3, pp. 122-37, Jul 2016, doi: 10.1159/000446586.

[9] K. A. Phillips, M. P. Douglas, S. Wordsworth, J. Buchanan, and D. A. Marshall, "Availability and funding of clinical genomic sequencing globally," *BMJ Glob Health,* vol. 6, no. 2, Feb 2021, doi: 10.1136/bmjgh-2020-004415.

[10] Y. S. Ng *et al.*, "Mitochondrial disease in adults: recent advances and future promise," *Lancet Neurol,* vol. 20, no. 7, pp. 573-584, Jul 2021, doi: 10.1016/S1474-4422(21)00098-3.

[11] E. Pirinen *et al.*, "Niacin Cures Systemic NAD(+) Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy," *Cell Metab,* vol. 32, no. 1, p. 144, Jul 7 2020, doi: 10.1016/j.cmet.2020.05.020.

[12] P. W. Stacpoole, "Why are there no proven therapies for genetic mitochondrial diseases?," *Mitochondrion,* vol. 11, no. 5, pp. 679-85, Sep 2011, doi: 10.1016/j.mito.2011.05.002.

[13] D. M. Sproule and P. Kaufmann, "Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome," *Ann N Y Acad Sci,* vol. 1142, pp. 133-58, Oct 2008, doi: 10.1196/annals.1444.011.

[14] A. Gaikwad, D. J. Long, 2nd, J. L. Stringer, and A. K. Jaiswal, "In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue," *J Biol Chem,* vol. 276, no. 25, pp. 22559-64, Jun 22 2001, doi: 10.1074/jbc.M101053200.

[15] A. K. Jaiswal, "Regulation of genes encoding NAD(P)H:quinone oxidoreductases," *Free Radic Biol Med,* vol. 29, no. 3-4, pp. 254-62, Aug 2000, doi: 10.1016/s0891-5849(00)00306-3.

[16] D. Ross, J. K. Kepa, S. L. Winski, H. D. Beall, A. Anwar, and D. Siegel, "NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms," *Chem Biol Interact,* vol. 129, no. 1-2, pp. 77-97, Dec 1 2000, doi: 10.1016/s0009-2797(00)00199-x.

[17] R. H. Houtkooper, C. Canto, R. J. Wanders, and J. Auwerx, "The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways," *Endocr Rev,* vol. 31, no. 2, pp. 194-223, Apr 2010, doi: 10.1210/er.2009-0026.

[18] H. Vaziri *et al.*, "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase," *Cell,* vol. 107, no. 2, pp. 149-59, Oct 19 2001, doi: 10.1016/s0092-8674(01)00527-x.

[19] F. R. Jornayvaz and G. I. Shulman, "Regulation of mitochondrial biogenesis," *Essays Biochem,* vol. 47, pp. 69-84, 2010, doi: 10.1042/bse0470069.

[20] K. S. Seo *et al.*, "KL1333, a Novel NAD(+) Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts," *Front Neurol,* vol. 9, p. 552, 2018, doi: 10.3389/fneur.2018.00552.

[21] G. S. Gorman *et al.* "A Phase 1a/1b Trial of KL1333 in Healthy Subjects and Patients with Primary Mitochondrial Disease." Abliva AB. https://www.youtube.com/watch?v=t86OAS0INc8 (accessed 2022.04.14.

[22] A. Schmidt, N. Endo, S. J. Rutledge, R. Vogel, D. Shinar, and G. A. Rodan, "Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator

and fatty acids," *Mol Endocrinol,* vol. 6, no. 10, pp. 1634-41, Oct 1992, doi: 10.1210/mend.6.10.1333051.

[23] S. A. Kliewer *et al.*, "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors," *Proc Natl Acad Sci U S A,* vol. 91, no. 15, pp. 7355-9, Jul 19 1994, doi: 10.1073/pnas.91.15.7355.

[24] K. Ravnskjaer, F. Frigerio, M. Boergesen, T. Nielsen, P. Maechler, and S. Mandrup, "PPARdelta is a fatty acid sensor that enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid-induced dysfunction," *J Lipid Res,* vol. 51, no. 6, pp. 1370-9, Jun 2010, doi: 10.1194/jlr.M001123.

[25] G. D. Barish, V. A. Narkar, and R. M. Evans, "PPAR delta: a dagger in the heart of the metabolic syndrome," *J Clin Invest,* vol. 116, no. 3, pp. 590-7, Mar 2006, doi: 10.1172/JCI27955.

[26] E. L. Bell *et al.*, "PPARdelta modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy," *Mitochondrion,* vol. 46, pp. 51-58, May 2019, doi: 10.1016/j.mito.2018.02.006.

[27] M. Ito *et al.*, "Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study," *Muscle Nerve,* vol. 65, no. 1, pp. 110-120, Jan 2022, doi: 10.1002/mus.27436.

[28] J. P. Stasch, P. Pacher, and O. V. Evgenov, "Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease," *Circulation,* vol. 123, no. 20, pp. 2263-73, May 24 2011, doi: 10.1161/CIRCULATIONAHA.110.981738.

[29] A. Friebe, P. Sandner, and A. Schmidtko, "cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development," *Naunyn Schmiedebergs Arch Pharmacol,* vol. 393, no. 2, pp. 287-302, Feb 2020, doi: 10.1007/s00210-019-01779-z.

[30] E. Nisoli *et al.*, "Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals," *Proc Natl Acad Sci U S A,* vol. 101, no. 47, pp. 16507-12, Nov 23 2004, doi: 10.1073/pnas.0405432101.

[31] S. S. Correia *et al.*, "The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases," *Front Pharmacol,* vol. 12, p. 656561, 2021, doi: 10.3389/fphar.2021.656561.

[32] R. J. Rodenburg, "Mitochondrial complex I-linked disease," *Biochim Biophys Acta,* vol. 1857, no. 7, pp. 938-45, Jul 2016, doi: 10.1016/j.bbabio.2016.02.012.

[33] S. B. Vafai and V. K. Mootha, "Mitochondrial disorders as windows into an ancient organelle," *Nature,* vol. 491, no. 7424, pp. 374-83, Nov 15 2012, doi: 10.1038/nature11707.

[34] J. K. Ehinger *et al.*, "Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency," *Nat Commun,* vol. 7, p. 12317, Aug 9 2016, doi: 10.1038/ncomms12317.

[35] Y. Chen, M. B. Azad, and S. B. Gibson, "Superoxide is the major reactive oxygen species regulating autophagy," *Cell Death Differ,* vol. 16, no. 7, pp. 1040-52, Jul 2009, doi: 10.1038/cdd.2009.49.

[36] I. G. Kirkinezos and C. T. Moraes, "Reactive oxygen species and mitochondrial diseases," *Semin Cell Dev Biol,* vol. 12, no. 6, pp. 449-57, Dec 2001, doi: 10.1006/scdb.2001.0282.

[37] X. Jiang *et al.*, "Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE2 biosynthesis by sonlicromanol's metabolite KH176m," *Sci Rep,* vol. 11, no. 1, p. 880, Jan 13 2021, doi: 10.1038/s41598-020-79466-w.

[38] M. C. H. Janssen *et al.*, "The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders," *Clin Pharmacol Ther,* vol. 105, no. 1, pp. 101-111, Jan 2019, doi: 10.1002/cpt.1197.

[39] J. Dudek, "Role of Cardiolipin in Mitochondrial Signaling Pathways," *Front Cell Dev Biol,* vol. 5, p. 90, 2017, doi: 10.3389/fcell.2017.00090.

[40] A. Karaa, R. Haas, A. Goldstein, J. Vockley, and B. H. Cohen, "A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy," *J Cachexia Sarcopenia Muscle,* vol. 11, no. 4, pp. 909-918, Aug 2020, doi: 10.1002/jcsm.12559.

[41] M. P. Siegel *et al.*, "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice," *Aging Cell,* vol. 12, no. 5, pp. 763-71, Oct 2013, doi: 10.1111/acel.12102.

[42] J. Dudek and C. Maack, "Barth syndrome cardiomyopathy," *Cardiovasc Res,* vol. 113, no. 4, pp. 399-410, Mar 15 2017, doi: 10.1093/cvr/cvx014.

[43] W. Reid Thompson *et al.*, "A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial

cardiolipin metabolism," *Genet Med,* vol. 23, no. 3, pp. 471-478, Mar 2021, doi: 10.1038/s41436-020-01006-8.
[44] W. D. Shrader *et al.*, "alpha-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging," *Bioorg Med Chem Lett,* vol. 21, no. 12, pp. 3693-8, Jun 15 2011, doi: 10.1016/j.bmcl.2011.04.085.
[45] G. M. Enns *et al.*, "Initial experience in the treatment of inherited mitochondrial disease with EPI-743," *Mol Genet Metab,* vol. 105, no. 1, pp. 91-102, Jan 2012, doi: 10.1016/j.ymgme.2011.10.009.
[46] A. Pastore *et al.*, "Glutathione: a redox signature in monitoring EPI-743 therapy in children with mitochondrial encephalomyopathies," *Mol Genet Metab,* vol. 109, no. 2, pp. 208-14, Jun 2013, doi: 10.1016/j.ymgme.2013.03.011.
[47] A. H. Kahn-Kirby *et al.*, "Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy," *PLoS One,* vol. 14, no. 3, p. e0214250, 2019, doi: 10.1371/journal.pone.0214250.
[48] A. D. Roberts and R. Wadhwa, "Orphan Drug Approval Laws," in *StatPearls*. Treasure Island (FL), 2022.
[49] A. Y. L. Chan *et al.*, "Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis," *Value Health,* vol. 23, no. 12, pp. 1580-1591, Dec 2020, doi: 10.1016/j.jval.2020.06.020.

Supplementary Table 1. Ongoing* clinical trials of primary mitochondrial diseases

Molecule: company	MoA	Clinical trials				
		Indication	**Study acronym**	**Phase**	**ClinicalTrials.gov Identifier**	**Efficacy: Primary endpoint**
Bocidelpar (ASP0367): Astellas	PPARδ agonist	Primary Mitochondrial Myopathy	MOUNTAINSIDE	II and III	NCT04641962	6-minute walk test
Elamipretide (MTP-131): Stealth Biotherapeutics	Cardiolipin-binding peptide	Primary mitochondrial myopathy with nuclear DNA mutations	NuPower	III	NCT05162768	6-minute walk test
IW-6463 (CY6463): Cyclerion Therapeutics	Guanylate cyclase stimulator	MELAS with neurological features	-	IIa	NCT04475549	-
KL1333: Abliva AB	NAD^+/NADH modulator	Primary mitochondrial disease (mtDNA)	FALCON	II and III	-	Fatigue and 30 s sit-to-stand
MT1621: Modis Therapeutics/ Zogenix (UCP)	Pyrimidine nucleosides	TK2 deficiency	-	IIIb	NCT04581733	Proportion of subjects acquiring a motor milestone
REN001: Reneo Pharmaceuticals	PPARδ agonist	Primary Mitochondrial Myopathy	STRIDE	II	NCT04535609	6-minute walk test
			STRIDE AHEAD	II and III	NCT05267574	-
Sonlicromanol (KH176): Khondrion BV	ROS-Redox modulator	m.3243A>G-associated disease with attentional dysfunction	KHENERGYZE	IIb	NCT04165239	Cognitive functioning: Attention
			KHENEREXT	IIb	NCT04604548	-
		Children with mitochondrial disease and motor symptoms	KHENERGYC	II	NCT04846036	Motor Symptom Severity
Vatiquinone (PTC743 and EPI-743): PTC Therapeutics	Oxidative stress modulator	Mitochondrial Disease with Refractory Epilepsy	MIT-E	II and III	NCT04378075	Number of motor seizures

* Recruiting, not yet recruiting, or active (not recruiting) trials investigating small molecules.